Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Characterization of a Cyclic Dinucleotide Metabolic Switch to Fuel Antitumor Immunity

Jeremy A. Meier, Katie E. Hurst, David L. Corcoran, Jessica E. Thaxton, Jonathan S. Serody

Blood (2022) 140 (Supplement 1): 4526–4527.

https://doi.org/10.1182/blood-2022-169006

Published: 2022

Journal Articles

Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma

Timothy J. Voorhees, Anne W. Beaven, Christopher Dittus, George E Hucks, J. Kaitlin Morrison, Catherine Joyce Arago Cheng, Tammy Cavallo, Steven I. Park, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo, Natalie S. Grover

Blood (2022) 140 (Supplement 1): 12723–12724.

https://doi.org/10.1182/blood-2022-156660

Published: 2022

Journal Articles

Cytotoxic Therapy Impairs the Stromal Niche Supporting ILC Development in the Bone Marrow

Oleg Kolupaev, Danny W. Bruce, Sonia J. Laurie, Hemamalini Bommiasamy, Jonathan S. Serody

Blood (2022) 140 (Supplement 1): 10231–10232.

https://doi.org/10.1182/blood-2022-165374

Published: 2022

Journal Articles

Amphiregulin Derived from Multiple Sources Is Important for Barrier Function of the Intestine Following Hematopoietic Stem Cell Transplantation

Danny W. Bruce, Oleg Kolupaev, Sonia J. Laurie, Hemamalini Bommiasamy, Jonathan S. Serody

Blood (2022) 140 (Supplement 1): 10208.

https://doi.org/10.1182/blood-2022-169051

Published: 2022

Journal Articles

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Joseph Rimando, Leslie Cope, Karen McKinnon, Benjamin G. Vincent, Sergio Rutella, Joshua F. Zeidner, Jonathan S. Serody, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 6314–6315.

https://doi.org/10.1182/blood-2022-165458

Published: 2022

Journal Articles

Absence of ILC2 Recovery Post-Transplant Is Mediated By Epigenetic Conversion of ILC2 to Pro-Inflammatory ILC1-like Cells

Sonia J. Laurie, Joseph P. Foster, II, Danny W. Bruce, Hemamalini Bommiasamy, Samantha G. Pattenden, Ian J. Davis, Jonathan S. Serody

Blood (2022) 140 (Supplement 1): 4461–4462.

https://doi.org/10.1182/blood-2022-167045

Published: 2022

Journal Articles

Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie S. Grover, Paul M. Armistead, James M. Coghill, Jr., Katarzyna Joanna Jamieson, Robert Hagan, J. Kaitlin Morrison, Faith Brianne Buchanan, Catherine Joyce Arago Cheng, Anastasia Ivanova, Tammy Cavallo, John West, Megan Gonzalez, Jonathan S. Serody, Gianpietro Dotti

Blood (2022) 140 (Supplement 1): 7437–7438.

https://doi.org/10.1182/blood-2022-165558

Published: 2022

Journal Articles

BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes

Blood (2022) 139 (19): 2983–2997.

https://doi.org/10.1182/blood.2021014557

Published: 2022

Includes: Supplemental data

Journal Articles

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

George E. Hucks, Jr., Barbara Savoldo, Gianpietro Dotti, Catherine Joyce Arago Cheng, Caroline Babinec, Kimberly A. Kasow, Michael Winstead, Arpita Patel, Cammie Presler, Natalie S Grover, J. Kaitlin Morrison, Anne W. Beaven, Marcie L. Riches, Thomas C. Shea, Jonathan S. Serody

Blood (2021) 138 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2021-153968

Published: 2021

Journal Articles

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

Natalie S Grover, Anastasia Ivanova, Dominic T. Moore, Catherine Joyce Arago Cheng, Caroline Babinec, John West, Tammy Cavallo, J. Kaitlin Morrison, Faith Brianne Buchanan, Edith Bowers, Christopher Dittus, Anne W. Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo

Blood (2021) 138 (Supplement 1): 742.

https://doi.org/10.1182/blood-2021-148102

Published: 2021

Journal Articles

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

Blood (2021) 137 (8): 1090–1103.

https://doi.org/10.1182/blood.2020005628

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Nicholas P. Tschernia, MD, Vaibhav Kumar, MBBS,MS, Dominic T. Moore, MPH, MS, Benjamin G. Vincent, MD, Callie C. Coombs, MD, Hendrik Van Deventer, MD, Matthew C. Foster, MD, Amy E. DeZern, MD, Leo Luznik, MD, Marcie L. Riches, MDMS, Jonathan S. Serody, MD, Ivana Gojo, MD, Joshua F. Zeidner, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-138786

Published: 2020

Journal Articles

Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Matthew C Foster, MD, Philip A. Roehrs, MD, George E Hucks, MD, Natalie S Grover, MD, Paul M. Armistead, MD PhD, Katarzyna Jamieson, MD, Faith Brianne Buchanan, PA, J. Kaitlin C Morrison, PhD, Spencer Laing, BA, Catherine Joyce Arago Cheng, BS, Jonathan S. Serody, MD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139051

Published: 2020

Journal Articles

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Blood (2020) 135 (1): 28–40.

https://doi.org/10.1182/blood.2019000032

Published: 2020

Includes: Supplemental data

Journal Articles

Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD

Danny W. Bruce, PhD, Oleg Kolupaev, PhD, Hemamalini Bommiasamy, PhD, Heather Stefanski, MD PhD, Bruce R. Blazar, MD, James M. Coghill, Jr., MD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3205.

https://doi.org/10.1182/blood-2019-126848

Published: 2019

Journal Articles

Epigenetic Plasticity of Type II Innate Lymphoid Cells in the Lower Gastrointestinal Tract

Sonia J. Laurie, PhD BSc, Danny W. Bruce, PhD, Hemamalini Bommiasamy, PhD, Melodie P Noel, BS, Joseph P. Foster, III, PhD, Ian J. Davis, MD PhD, Samantha G. Pattenden, PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 1921.

https://doi.org/10.1182/blood-2019-126823

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Timothy J Voorhees, MD, Natalie S Grover, MD, Anne Beaven, MD, Steven I Park, MD, J. Kaitlin Morrison, PhD, Catherine Joyce Arago Cheng, BS, Spencer Laing, BA, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3233.

https://doi.org/10.1182/blood-2019-122846

Published: 2019

Journal Articles

Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD

Blood (2019) 134 (19): 1670–1682.

https://doi.org/10.1182/blood.2019001950

Published: 2019

NARROW

Characterization of a Cyclic Dinucleotide Metabolic Switch to Fuel Antitumor Immunity

Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma

Cytotoxic Therapy Impairs the Stromal Niche Supporting ILC Development in the Bone Marrow

Amphiregulin Derived from Multiple Sources Is Important for Barrier Function of the Intestine Following Hematopoietic Stem Cell Transplantation

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Absence of ILC2 Recovery Post-Transplant Is Mediated By Epigenetic Conversion of ILC2 to Pro-Inflammatory ILC1-like Cells

Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates

BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD

Epigenetic Plasticity of Type II Innate Lymphoid Cells in the Lower Gastrointestinal Tract

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only